Assessment of mitochondrial toxicity in newborns and infants with congenital cytomegalovirus infection treated with valganciclovir
BACKGROUND: Ganciclovir/valganciclovir is currently indicated during the first 6 months of life in symptomatic children with congenital cytomegalovirus (CMV) infection. However, this treatment may have the potential to induce mitochondrial toxicity due to off-target inhibition of DNA-polymerases. Si...
Main Authors: | Cantó-Santos, J. (Author), Cardellach, F. (Author), Fortuny, C. (Author), García-García, F.J (Author), Garrabou, G. (Author), Grau, J.M (Author), Morén, C. (Author), Noguera-Julian, A. (Author), Ortiz-Gracia, A. (Author), Ríos, M. (Author), Sánchez, E. (Author), Tobías, E. (Author), Valls-Roca, L. (Author) |
---|---|
Format: | Article |
Language: | English |
Published: |
NLM (Medline)
2022
|
Subjects: | |
Online Access: | View Fulltext in Publisher |
Similar Items
-
Coxsackievirus B3 Infection and Host Defence Responses Change the Metabolism of PBDE
by: Lundgren, Magnus
Published: (2009) -
Effects of oral valganciclovir prophylaxis for cytomegalovirus infection in heart transplant patients
by: Doesch AO, et al.
Published: (2012-10-01) -
Valganciclovir in the treatment of cytomegalovirus retinitis in HIV-infected patients
by: A Jayaprakash Patil, et al.
Published: (2010-03-01) -
Cytomegalovirus viraemia in immunocompromised children in Cape Town
by: Hsiao, Nei-Yuan
Published: (2014) -
Letermovir for Cytomegalovirus Prophylaxis in Lung Transplant Patients with Valganciclovir-Induced Leukopenia
by: Arindam Singha, et al.
Published: (2021-04-01)